Scientific Presentations

Categories

Clinical Update from Phase 1/2 ABILITY Study

Source

R&D day, 2023

Planning of a Phase 3 Randomized Controlled Trial Incorporating an External Control Arm

Source

National Brain Tumor Society, 2023

Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment

Source

American Association for Cancer Research (AACR) Annual Meeting, 2023

Early Results of an IL-2 Superkine (MDNA11) from the Phase 1/2 ABILITY Study in Advanced Solid Tumors

Source

2023 Immunotherapy Bridge Conference, 2022

The Promise of Interlukin-2 Therapy Conference

Source

The Promise of IL-2 Therapy (Paris, France), 2022

Co-Stimulation of Adaptive and Innate Immune Cells to Achieve Clinical Benefit with MDNA11, a Long-Acting ‘Betaonly’ IL-2 Super-Agonist

Source

Cytokine Based Drug Development Summit, 2022

MDNA11 is a Long-Acting ‘Beta-Only’ IL-2 Agonist Exhibiting Potent Tumor Growth Control in Preclinical Models and Preferential Expansion of NK and CD8+ T Cells in Patients with Advanced Solid Tumors

Source

Frontiers in Cancer Immunotherapy 2022

MDNA11 Phase 1/2 ABILITY Study in Advanced Solid Tumors

Source

12th Annual LifeSci Partners Corporate Access Event, 2022

MDNA11 is a Long-Acting ‘Beta-Only’ IL-2 Agonist that Demonstrates Safe and Durable Anti-Tumor Immune Response

Source

AACR-NCI-EORTC Virtual International Conference On Molecular Targets and Cancer Therapeutics, 2021

Evolutionary IL-2 Superkines: Past, Present and Future

Source

Next-Gen Cytokine Therapeutics Summit, 2021

MDNA55 survival in recurrent glioblastoma ("rGBM") patients expressing the interleukin-4 receptor ("IL4R") as compared to a matched synthetic control

Source

2021

Modulation of Immune Responses to Cancer With Bi-specific IL-2/IL-13 Superkines

Source

American Association for Cancer Research (AACR) Annual Meeting, 2022

Designer cytotoxins

Source

Cytokine-Based Cancer Immunotherapies Summit, 2021

MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme

Source

KOL day, 2020

MDNA55, an IL4-Guided Toxin in Recurrent GBM: Phase 2b Results and Use of an External Control Arm in a Registration Trial

Source

3rd Annual Glioblastoma Drug Development Summit, 2020

Designer Superkines: Modulating Immune Cells of Choice

Source

Next-Gen Cytokine Therapeutics Summit, 2020

In vitro and in vivo characteristics of MDNA11: A long-acting 'Beta-only' IL-2 Superkine in syngeneic mice tumor models and non-human primates

Source

ASCO, 2020

IL-2 Superkine, MDNA19, Non-Human Primate Study

Source

webcast, 2020

Using a Multi-pronged Approach to Treating Recurrent GBM – Overcoming the Tumor and its Microenvironment

Source

Inaugural Glioblastoma Drug Development Annual Summit, 2019

RSS Feeds

Print Page

Email Alerts

Document Request